Evidence map›Paper›PMID 34159518›Full record

ArticleInternational journal of hematology2021

A case of lymphomatoid granulomatosis with central nervous system involvement successfully treated with IFNα.

Yoshitaka Yamasaki, Satoshi Morishige, Satoru Komaki, Takuya Furuta, Hiroshi Koga, Shuki Oya, Takayuki Nakamura, Maki Yamaguchi, Kazutoshi Aoyama, Fumihiko Mouri and 5 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Yoshitaka YamasakiDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Satoshi MorishigeDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan. morishige_satoshi@kurume-u.ac.jp.ORCID http://orcid.org/0000-0002-6605-6870
Satoru KomakiDepartment of Neurosurgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Takuya FurutaDepartment of Pathology, School of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Hiroshi KogaDepartment of Dermatology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Shuki OyaDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Takayuki NakamuraDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Maki YamaguchiDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Kazutoshi AoyamaDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Fumihiko MouriDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Koichi OsakiDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Takekuni NakamaDepartment of Dermatology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Koichi OhshimaDepartment of Pathology, School of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Motohiro MoriokaDepartment of Neurosurgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Koji NagafujiDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Kurume University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr virus (EBV)-driven B-cell lymphoproliferative disease affecting mainly extranodal sites such as the lung, central nervous system (CNS), skin, kidney, and liver. We report a case of low-grade LYG involving the CNS that was successfully treated with interferon alpha (IFNα). A 69-year-old woman developed necrotic erythema of the skin and was initially diagnosed with pyoderma gangrenosum based on skin biopsy. She showed a limited response to prednisolone. Approximately 6 months after the initial onset, low-grade LYG was diagnosed after detection of CNS lesions on brain biopsy. The whole blood EBV-DNA load determined by real-time polymerase chain reaction was slightly elevated. Two months into IFNα therapy, skin and CNS lesions had responded favorably and the EBV-DNA load decreased. IFNα plays an important role in treatment of LYG through its antiproliferative, immunomodulatory, and anti-EBV effects. To our knowledge, this is the first case report of successful treatment with IFNα in Japan. Further investigation is necessary to determine optimal use of IFNα for LYG.

Indexed as

AgedBiomarkersBiopsyCentral Nervous System NeoplasmsClonal EvolutionFemaleHumansImmunohistochemistryInterferon-alphaLymphomatoid GranulomatosisMagnetic Resonance ImagingSymptom AssessmentTomography, X-Ray ComputedTreatment OutcomeBiomarkersInterferon-alphaCentral nervous systemEpstein–Barr virusInterferon alphaLymphomatoid granulomatosis

Identifiers

PMID34159518
OpenAlexW3176726416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.